PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers

PEGylation is the technology involving the covalent attachment of polyethylene glycol (PEG) to a protein‐, peptide‐ or small‐molecule drug to improve their pharmacokinetic, pharmacodynamic and immunological profiles, and thus, enhance the therapeutic effect. Today, PEGylation of proteins is a well‐established technology and is being used in the treatment of a variety of clinical disorders. Several PEGylated coagulation proteins for haemophilia A and B are under development with the goal of prolonging the circulation half‐life of factor VIII (FVIII) or factor IX. The prolongation of half‐life, resulting in less frequent injections can provide significant benefits in improving the quality of life of subjects with haemophilia and improvement in adherence to treatment. A review of published literature on PEGylated therapeutic products currently approved for human use and a discussion of a PEGylated recombinant FVIII molecule (BAY 94–9027, Bayer HealthCare, Berkeley, CA, USA) currently being investigated in the pivotal clinical trial prior to registration is provided. Available safety information of PEGylated proteins containing high molecular weight PEG does not indicate any safety concerns to date, following long‐term (chronic) use in animal models or patients. Chronic use of currently available PEGylated products has been shown to be safe, paving the way for chronic use of PEGylated coagulation products in persons with haemophilia.

[1]  H. Ehrlich,et al.  Safety of Baxter’s Longer Acting rFVIII (BAX 855) After Repeated Application in Rats and Cynomolgus Monkeys , 2011 .

[2]  P. Giangrande,et al.  Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. , 2011, Blood.

[3]  M. Cottone,et al.  Certolizumab pegol for the treatment of rheumatoid arthritis , 2011 .

[4]  G. Rogler,et al.  Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26‐week data of the FACTS II survey , 2011, Inflammatory bowel diseases.

[5]  A. Rosholm,et al.  Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects , 2011, Journal of thrombosis and haemostasis : JTH.

[6]  A. Baas,et al.  FDA-approved poly(ethylene glycol)–protein conjugate drugs , 2011 .

[7]  I. Delgado,et al.  Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis , 2011, Pediatric Nephrology.

[8]  I. Ivens,et al.  BAY 94–9027, a PEGylated Recombinant Human FVIII, Shows Less Immunogenicity Compared to Un-PEGylated Recombinant FVIII , 2010 .

[9]  P. Mease.  Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety , 2010, Rheumatology.

[10]  John E. Murphy,et al.  Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. , 2010, Blood.

[11]  D. Fliser,et al.  Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study , 2010, Current medical research and opinion.

[12]  F. C. Dougherty,et al.  C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. , 2010, Clinical nephrology.

[13]  Simona Jevševar,et al.  PEGylation of therapeutic proteins , 2010, Biotechnology journal.

[14]  Kang-Choon Lee,et al.  Emerging PEGylated drugs , 2009, Expert opinion on emerging drugs.

[15]  Kristi S. Anseth,et al.  PEG Hydrogels for the Controlled Release of Biomolecules in Regenerative Medicine , 2009, Pharmaceutical Research.

[16]  D. Strickland,et al.  LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. , 2008, Physiological reviews.

[17]  G. Pasut,et al.  Polymer-drug conjugation, recent achievements and general strategies , 2007 .

[18]  P. Lenting,et al.  Clearance mechanisms of von Willebrand factor and factor VIII , 2007, Journal of thrombosis and haemostasis : JTH.

[19]  A. Malavalli,et al.  Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. , 2007, Translational research : the journal of laboratory and clinical medicine.

[20]  J. Stadler,et al.  PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies , 2007, Drug Metabolism and Disposition.

[21]  A. Azadi,et al.  Pharmacokinetic Consequences of Pegylation , 2006, Drug delivery.

[22]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[23]  R. Ljung,et al.  Optimizing factor prophylaxis for the haemophilia population: where do we stand? , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  P. Caliceti,et al.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.

[25]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[26]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[27]  J. Sims,et al.  The industry view on long-term toxicology testing in drug development of human pharmaceuticals. , 2000, Pharmacology & toxicology.

[28]  E. Åkerblom,et al.  B-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol. , 2000, Bioconjugate chemistry.

[29]  G. Shopp,et al.  Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  L. Kwak,et al.  Conjugation of High-Molecular Weight Poly(ethylene glycol) to Cytokines: Granulocyte-Macrophage Colony-Stimulating Factors as Model Substrates , 1997 .

[31]  Y. Ikada,et al.  Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification , 1997 .

[32]  Y. Ikada,et al.  Fate of water-soluble polymers administered via different routes. , 1995, Journal of pharmaceutical sciences.

[33]  Y. Ikada,et al.  Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. , 1994, Journal of pharmaceutical sciences.

[34]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[35]  F. Veronese,et al.  The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.

[36]  P. Taupin,et al.  PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals , 2009 .

[37]  I. Mahmood,et al.  Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins , 2005, Clinical pharmacokinetics.

[38]  J. R. Scotti,et al.  Available From , 1973 .

[39]  R. Mehvar.  Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. , 2000, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.